Publicaciones en las que colabora con Pilar Coronel Granado (15)

2024

  1. Exploring therapeutic options for mild diabetic-related foot infections: a comparative in vitro study of cefditoren versus amoxicillin/clavulanic acid

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 37, Núm. 4, pp. 356-359

2011

  1. Efficacy of simulated cefditoren versus amoxicillin-clavulanate free concentrations in countering intrastrain ftsI gene diffusion in Haemophilus influenzae

    Antimicrobial Agents and Chemotherapy, Vol. 55, Núm. 6, pp. 2788-2794

2010

  1. Cefditoren versus ceftazidime in inducersubstrate combinations for the evaluation of AmpC production in a disc approximation test

    Revista Espanola de Quimioterapia, Vol. 23, Núm. 2, pp. 72-75

  2. Enhanced in vivo activity of cefditoren in preimmunized mice against penicillin-resistant S. pneumoniae (Serotypes 6B, 19F and 23F) in a sepsis model

    PLoS ONE, Vol. 5, Núm. 8

  3. In vitro interference of β-lactams with biofilm development by prevalent community respiratory tract isolates

    International Journal of Antimicrobial Agents, Vol. 35, Núm. 3, pp. 274-277

2009

  1. Genotypic versus phenotypic characterization, with respect to β-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to β-lactam resistance markers

    Antimicrobial Agents and Chemotherapy, Vol. 53, Núm. 1, pp. 267-270

  2. Influence of different resistance traits on the competitive growth of Haemophilus influenzae in antibiotic-free medium and selection of resistant populations by different β-lactams: An in vitro pharmacodynamic approach

    Journal of Antimicrobial Chemotherapy, Vol. 63, Núm. 6, pp. 1215-1222

2008

  1. Decrease in bacterial load versus resistance selection of pneumococcal subpopulations by β-lactam physiological concentrations over time: An in vitro pharmacodynamic simulation

    Microbial Drug Resistance, Vol. 14, Núm. 1, pp. 13-21

  2. High protein binding and cidal activity against penicillin-resistant S. pneumoniae: A cefditoren in vitro pharmacodynamic simulation

    PLoS ONE, Vol. 3, Núm. 7

  3. Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of cefditoren-pivoxil

    Antimicrobial Agents and Chemotherapy, Vol. 52, Núm. 3, pp. 1184-1186

  4. β-Lactam effects on mixed cultures of common respiratory isolates as an approach to treatment effects on nasopharyngeal bacterial population dynamics

    PLoS ONE, Vol. 3, Núm. 12

  5. β-lactam activity against penicillin-resistant Streptococcus pneumoniae strains exhibiting higher amoxicillin versus penicillin minimum inhibitory concentration values: An in vitro pharmacodynamic simulation

    Chemotherapy, Vol. 54, Núm. 2, pp. 84-90

2007

  1. Are β-lactam breakpoints adequate to define non-susceptibility for all Haemophilus influenzae resistance phenotypes from a pharmacodynamic point of view?

    Journal of Antimicrobial Chemotherapy, Vol. 59, Núm. 4, pp. 652-657

  2. Effects of human albumin and serum on the in vitro bactericidal activity of cefditoren against penicillin-resistant Streptococcus pneumoniae

    Journal of Antimicrobial Chemotherapy, Vol. 60, Núm. 1, pp. 156-158

  3. Influence of TEM-1 β-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhibiting an N526K mutation in the ftsI gene

    Antimicrobial Agents and Chemotherapy, Vol. 51, Núm. 10, pp. 3699-3706